Huijuan Fan

Huijuan Fan

Auto-generated profile, based on publicly available information

Huijuan Fan

State Key Laboratory of Molecular Oncology and Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2023 in Cancer Research
Verified
Journal Article
Closed access
PDF file
HFHuijuan Fan
Huijuan Fan
ZXZhanao Xu
Zhanao Xu
KYKe Yao
Ke Yao
BZBingxin Zheng
Bingxin Zheng
YZYuan Zhang
Yuan Zhang
HZHanqiu Zheng
Hanqiu Zheng
The majority of patients with late-stage breast cancer develop distal bone metastases. The bone microenvironment can affect response to therapy, and uncovering the underlying mechanisms could help identify improved strategies for treating bone metastatic breast cancer. Here, we observed that osteoclasts reduced the sensitivity of breast cancer cells to DNA damaging agents, including cisplatin and the PARP inhibitor (PARPi) olaparib. Metabolic profiling identified elevated glutamine production by osteoclasts. Glutamine supplementation enhanced the survival of breast cancer cells treated with DNA damaging agents, while blocking glutamine uptake increased sensitivity and suppressed bone metastasis. GPX4, the critical enzyme responsible for glutathione oxidation, was upregulated in cancer cells following PARPi treatment through stress-induced ATF4-dependent transcriptional programming. Increased glutamine uptake and GPX4 upregulation concertedly enhanced glutathione metabolism in cancer cells to help neutralize oxidative stress and generate PARPi resistance. Analysis of paired patient samples of primary breast tumors and bone metastases revealed significant induction of GPX4 in bone metastases. Combination therapy utilizing PARPi and zoledronate, which blocks osteoclast activity and thereby reduces the microenvironmental glutamine supply, generated a synergistic effect in reducing bone metastasis. These results identify a role for glutamine production by bone-resident cells in supporting metastatic cancer cells to overcome oxidative stress and develop resistance to DNA-damaging therapies. Significance: Metabolic interaction between osteoclasts and tumor cells contributes to resistance to DNA-damaging agents, which can be blocked by combination treatment with PARP and osteoclast inhibitors to reduce bone metastatic burden.

1 February 2024
Verified
Other
Open access
HFHuijuan Fan
Huijuan Fan
ZXZhanao Xu
Zhanao Xu
KYKe Yao
Ke Yao
BZBingxin Zheng
Bingxin Zheng
YZYuan Zhang
Yuan Zhang
HZHanqiu Zheng
Hanqiu Zheng
Metabolomics of primary tumors vs bone metastasis


1 February 2024
Verified
Other
Open access
HFHuijuan Fan
Huijuan Fan
ZXZhanao Xu
Zhanao Xu
KYKe Yao
Ke Yao
BZBingxin Zheng
Bingxin Zheng
YZYuan Zhang
Yuan Zhang
HZHanqiu Zheng
Hanqiu Zheng
Supplementary Video S1 is related to Figure 5 (Vehicle-only group).

1 February 2024
Verified
Other
Open access
HFHuijuan Fan
Huijuan Fan
ZXZhanao Xu
Zhanao Xu
KYKe Yao
Ke Yao
BZBingxin Zheng
Bingxin Zheng
YZYuan Zhang
Yuan Zhang
HZHanqiu Zheng
Hanqiu Zheng
Metabolomics of macrophages vs osteaoclasts